309 related articles for article (PubMed ID: 20502000)
21. Acid sphingomyelinase - a regulator of canonical transient receptor potential channel 6 (TRPC6) activity.
Zeitler S; Ye L; Andreyeva A; Schumacher F; Monti J; Nürnberg B; Nowak G; Kleuser B; Reichel M; Fejtová A; Kornhuber J; Rhein C; Friedland K
J Neurochem; 2019 Sep; 150(6):678-690. PubMed ID: 31310676
[TBL] [Abstract][Full Text] [Related]
22. Role of acid sphingomyelinase in the regulation of mast cell function.
Yang W; Schmid E; Nurbaeva MK; Szteyn K; Leibrock C; Yan J; Schaller M; Gulbins E; Shumilina E; Lang F
Clin Exp Allergy; 2014 Jan; 44(1):79-90. PubMed ID: 24164338
[TBL] [Abstract][Full Text] [Related]
23. Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target.
Zhuo C; Zhao F; Tian H; Chen J; Li Q; Yang L; Ping J; Li R; Wang L; Xu Y; Cai Z; Song X
Transl Psychiatry; 2022 Jun; 12(1):260. PubMed ID: 35739089
[TBL] [Abstract][Full Text] [Related]
24. Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model.
Yang K; Nong K; Gu Q; Dong J; Wang J
Eur J Med Chem; 2018 May; 151():389-400. PubMed ID: 29649738
[TBL] [Abstract][Full Text] [Related]
25. Use of acid sphingomyelinase for cancer therapy.
Savić R; Schuchman EH
Adv Cancer Res; 2013; 117():91-115. PubMed ID: 23290778
[TBL] [Abstract][Full Text] [Related]
26. Modulating cancer cell survival by targeting intracellular cholesterol transport.
Kuzu OF; Gowda R; Noory MA; Robertson GP
Br J Cancer; 2017 Aug; 117(4):513-524. PubMed ID: 28697173
[TBL] [Abstract][Full Text] [Related]
27. Small molecule inhibitors of acid sphingomyelinase.
Arenz C
Cell Physiol Biochem; 2010; 26(1):1-8. PubMed ID: 20501999
[TBL] [Abstract][Full Text] [Related]
28. Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis.
Cho SM; Kwon HJ
Arch Pharm Res; 2019 Mar; 42(3):232-243. PubMed ID: 30661200
[TBL] [Abstract][Full Text] [Related]
29. Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's disease.
Choi BJ; Park MH; Jin HK; Bae JS
Exp Mol Med; 2024 Feb; 56(2):301-310. PubMed ID: 38337058
[TBL] [Abstract][Full Text] [Related]
30. Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?
Le Corre P; Loas G
J Clin Pharm Ther; 2021 Oct; 46(5):1213-1219. PubMed ID: 33645763
[TBL] [Abstract][Full Text] [Related]
31. Increased acid sphingomyelinase levels in pediatric patients with obesity.
Mameli C; Carnovale C; Ambrogi F; Infante G; Biejat PR; Napoli A; Coazzoli M; Calcaterra V; Schneider L; Perazzi C; Zuccotti G; Clementi E; Moscheni C; Perrotta C
Sci Rep; 2022 Jun; 12(1):10996. PubMed ID: 35768443
[TBL] [Abstract][Full Text] [Related]
32. Doxepin Mitigates Noise-induced Neuronal Damage in Primary Auditory Cortex of Mice via Suppression of Acid Sphingomyelinase/Ceramide Pathway.
Su YT; Meng XX; Zhang X; Guo YB; Zhang HJ; Cheng YP; Xie XP; Chang YM; Bao JX
Anat Rec (Hoboken); 2017 Dec; 300(12):2220-2232. PubMed ID: 28806500
[TBL] [Abstract][Full Text] [Related]
33. Role of acid sphingomyelinase bioactivity in human CD4+ T-cell activation and immune responses.
Bai A; Kokkotou E; Zheng Y; Robson SC
Cell Death Dis; 2015 Jul; 6(7):e1828. PubMed ID: 26203857
[TBL] [Abstract][Full Text] [Related]
34. Homocysteine induces cerebral endothelial cell death by activating the acid sphingomyelinase ceramide pathway.
Lee JT; Peng GS; Chen SY; Hsu CH; Lin CC; Cheng CA; Hsu YD; Lin JC
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():21-7. PubMed ID: 23665108
[TBL] [Abstract][Full Text] [Related]
35.
Pauletto P; Bortoli M; Bright FO; Delgado CP; Nogara PA; Orian L; da Rocha JBT
J Biomol Struct Dyn; 2023 Nov; 41(19):9562-9575. PubMed ID: 36447407
[TBL] [Abstract][Full Text] [Related]
36. The lysosomal trafficking of acid sphingomyelinase is mediated by sortilin and mannose 6-phosphate receptor.
Ni X; Morales CR
Traffic; 2006 Jul; 7(7):889-902. PubMed ID: 16787399
[TBL] [Abstract][Full Text] [Related]
37. The role of ceramide in major depressive disorder.
Kornhuber J; Reichel M; Tripal P; Groemer TW; Henkel AW; Mühle C; Gulbins E
Eur Arch Psychiatry Clin Neurosci; 2009 Nov; 259 Suppl 2():S199-204. PubMed ID: 19876679
[TBL] [Abstract][Full Text] [Related]
38. Sphingomyelin analogues as inhibitors of sphingomyelinase.
Taguchi M; Sugimoto K; Goda K; Akama T; Yamamoto K; Suzuki T; Tomishima Y; Nishiguchi M; Arai K; Takahashi K; Kobori T
Bioorg Med Chem Lett; 2003 Jun; 13(12):1963-6. PubMed ID: 12781174
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of xanthone derivatives as acid sphingomyelinase inhibitors: potential treatment for UV-induced skin damage.
Yang K; Gao B; Ming X; Huang Z; Wang M; Dong J; Wang J
Future Med Chem; 2017 Oct; 9(16):1887-1898. PubMed ID: 29076348
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol-3,5-Bisphosphate is a potent and selective inhibitor of acid sphingomyelinase.
Kölzer M; Arenz C; Ferlinz K; Werth N; Schulze H; Klingenstein R; Sandhoff K
Biol Chem; 2003 Sep; 384(9):1293-8. PubMed ID: 14515991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
